A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

por Danese, S, Dignass, A, Matsuoka, K, Ferrante, M, Long, M, Redondo, I, Gibble, T H, Moses, R, Morris, N, Li, X, Milch, C, Abreu, M, Jones, J
Publicado 2023

A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

por Dignass, A, Danese, S, Matsuoka, K, Ferrante, M, Long, M, Redondo, I, Gibble, T H, Moses, R, Li, X, Morris, N, Milch, C, Abreu, M, Jones, J
Publicado 2023

The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method

por Reinisch, W, Chowers, Y, Danese, S, Dignass, A, Gomollón, F, Haagen Nielsen, O, Lakatos, P L, Lees, C W, Lindgren, S, Lukas, M, Mantzaris, G J, Michetti, P, Moum, B, Peyrin-Biroulet, L, Toruner, M, Woude, J, Weiss, G, Stoevelaar, H
Publicado 2013